Analysis of combination anti-angiogenesis therapy on markers of coagulation, platelet activation and angiogenesis in patients with advanced cancer.
The effects of combination anti-angiogenesis therapy (marimastat, captopril and fragmin) on plasma levels of coagulation initiator tissue factor (TF), platelet marker soluble P-selectin and angiogenic vascular endothelial growth factor (VEGF) were tested in 25 patients with advanced cancer. They had higher soluble P-selectin (P<0.001) and TF (P<0.001), but not VEGF (P=0.066) than 25 age and sex-matched controls. VEGF and TF correlated significantly (r=0.8, P<0.001) in cancer patients. Soluble P-selectin, TF and VEGF did not change at 4- and 8-weeks whilst on treatment. We provide further evidence linking coagulation and angiogenesis but combination anti-angiogenesis therapy does not influence plasma soluble P-selectin, TF or VEGF.
Caine
G J
GJ
Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK.
Harris
A L
AL
Christodoulos
K
K
Lip
G Y H
GY
Blann
A D
AD
D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000925:Anticoagulants / Q000494:pharmacology; D002216:Captopril / Q000494:pharmacology; D017985:Dalteparin / Q000494:pharmacology; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood* / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D019007:P-Selectin / Q000097:blood*; D015539:Platelet Activation / Q000187:drug effects; D013925:Thromboplastin / Q000032:analysis*; D042461:Vascular Endothelial Growth Factor A / Q000097:blood*
D020533:Angiogenesis Inhibitors; D000925:Anticoagulants; D006877:Hydroxamic Acids; D019007:P-Selectin; D042461:Vascular Endothelial Growth Factor A; D013925:Thromboplastin; D002216:Captopril; C100342:marimastat; D017985:Dalteparin